+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 48 Actively Recruiting clinical trials

O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.

All AgesAll Genders
21 locations
L

Actively Recruiting

Researchers are studying an experimental combination of two drugs, pozelimab and cemdisiran, for adults with paroxysmal nocturnal hemoglobinuria PNH. This study aims to evaluate the long-term safety and effectiveness of this drug combination. It also investigates how the drugs affect the body over time, including possible side effects, drug levels in the blood, and whether the body develops antibodies against the drugs. The study includes two groups patients who completed treatment in a previous related study and patients with a specific genetic variation C5 polymorphism that makes them resistant to other treatments. Participants receive pozelimab with an initial intravenous loading dose on Day 1, followed by ongoing treatment with both study drugs as per the study protocol. The study is open-label and non-randomized. Participants will attend clinic visits and undergo various assessments throughout the study, including blood tests to measure lactate dehydrogenase LDH levels and monitor hemolysis, transfusion needs, hemoglobin levels, fatigue, physical function, and quality of life. Safety is closely monitored by tracking adverse events. The study lasts up to 108 weeks, allowing researchers to observe long-term treatment effects and safety.

Age: 18Years +All GendersPhase 3
48 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral Apabetalone combined with background dapagliflozin treatment for up to 12 weeks in adults with type 2 diabetes mellitus T2DM who have experienced probable or confirmed COVID-19 infection. Participants must have symptoms of Long COVID lasting at least 2 months within 3 months from the start of COVID-19, which cannot be explained by other diagnoses. This phase II, open-label multicentre trial aims to better understand treatment options for this group of patients. Participants will take oral Apabetalone 100 mg capsules twice daily with meals while continuing their daily dapagliflozin 10 mg therapy for diabetes. The study involves seven in-person clinic visits where data will be collected to assess the treatments effects. After screening and consent, eligible participants begin Apabetalone treatment on Day 1 and continue it at home under study supervision. During the trial, participants will undergo various assessments including symptom evaluations and functional status tools related to Long COVID. The primary outcome is the patient acceptable symptom state at 90 days. Secondary measures include fatigue, dyspnea, and post-exertional malaise assessments. Safety and adherence will be monitored throughout, with the total study duration covering treatment and follow-up visits over approximately 12 weeks.

Age: 18Years +All GendersPhase 2Phase 3
3 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.

Age: 18Years - 75YearsAll GendersPhase 2
276 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
T

Actively Recruiting

Autism spectrum disorders ASDs are complex neuro-developmental conditions characterized by ongoing difficulties in social communication and interaction, along with restricted and repetitive behaviors or interests. These disorders involve inflammatory conditions and immune system dysfunction, which has led researchers to explore cell-based therapies as a potential treatment. This study is a Phase 1 clinical trial focusing on evaluating the safety and effects of stem cells for children with ASD. Participants in the trial receive three intravenous doses of allogeneic Wharton Jelly Mesenchymal Stromal Cells WJMSC at a dose of 1 million cells per kilogram of body weight. These doses are administered every two weeks as the treatment approach. The study aims to assess both safety and efficacy over a follow-up period extending to 12 months after treatment. During the study, researchers monitor participants through laboratory tests to evaluate the safety profile of the treatment. They also measure changes in attention and hyperactivity symptoms using the Adult ADHD Self-Report Scale over a 12-month follow-up. The trial involves children aged 4 to 14 years diagnosed with ASD, with regular assessments and follow-up visits scheduled throughout the year to observe treatment effects and ensure participant safety.

Age: 4Years - 14YearsAll GendersPhase 1
1 location
I

Actively Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN is a very rare blood cancer with no agreed-upon best treatment. Researchers are working internationally to gather detailed information on how BPDCN presents, how it is diagnosed, the treatments patients receive, and their outcomes. The study aims to build a large database to better understand the disease and to develop treatment recommendations based on collected data. This study is an international registry collecting information from multiple centers about patients diagnosed with BPDCN. It includes both retrospective and prospective data from patients worldwide. The data collected covers patient details, disease characteristics, treatment information, outcomes, causes of death, and the conclusion of data collection. Consent will be obtained from prospective patients, and quality control is managed by the Immune Oncology Research Institute. Participants will provide information through questionnaires completed by their treatment centers. Researchers will analyze overall survival, complete remission rates, duration of first remission, and event-free survival over five years. This observational study does not involve treatment but gathers and monitors detailed clinical data to improve understanding and guide future therapies for BPDCN.

All AgesAll Genders
22 locations
E

Actively Recruiting

Researchers are evaluating the use of allogenic dentin grafts, derived from human-extracted teeth, for preserving the alveolar ridge after tooth extraction. This trial aims to test two types of grafts demineralized dentin allografts DDA and whole tooth allografts WTA, as alternatives to traditional autogenous bone grafts. These grafts may offer a sustainable and scalable solution by repurposing extracted teeth, which are usually discarded, and addressing the limitations of autogenous grafts such as donor site issues and limited availability. Participants will receive one of the two allogenic dentin grafts DDA or WTA applied to preserve the alveolar ridge following tooth extraction, or no graft in the control group. The study is prospective and non-randomized, focusing on clinical and radiographic evaluation. The grafts are prepared from healthy human donors, and the intervention supports innovative, sustainable dental practices. The trial includes a control group to compare outcomes without grafting. During the study, participants will undergo assessments including cone beam computed tomography CBCT scans to measure changes in alveolar ridge width and height from baseline to three months after extraction. Researchers will monitor the biocompatibility and effectiveness of the grafts by comparing these measurements across groups. The total follow-up period for primary outcomes is three months post-extraction, with evaluations of alveolar crest dimensions to support future prosthetic rehabilitation.

Age: 18Years - 60YearsAll GendersPhase 1Phase 2
1 location
E

Actively Recruiting

Researchers are studying the combined effect of sensory-motor integration on individuals with postmenopausal polyneuropathy, a condition affecting nerve function and balance. The study aims to improve balance and reduce pain in women who have peripheral neuropathy after menopause, especially those with Type II Diabetes Mellitus and numbness in their limbs lasting more than four months. Participants will be randomly assigned to one of two groups. One group will receive sensory motor integration therapy, which includes tactile, thermal, and proprioceptive stimulation along with strengthening exercises and pelvic rocking training for six weeks. The other group will receive conventional exercises, involving free and gymnasium exercises for the upper and lower limbs plus 20 minutes of walking. During the six-week study, participants will be assessed for pain intensity and balance. Researchers will monitor changes in these measures to understand the effects of the different exercise programs. The study is sponsored by New Ismailia National University and includes women aged 45 to 55 years. Participants progress and safety will be monitored throughout the trial period.

Age: 45Years - 55YearsFEMALEPhase Not Applicable
2 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating different implant abutment connection configurations in implant-supported screw-retained fixed dental prostheses. The study aims to compare clinical and radiographic outcomes to determine which abutment connection results in fewer biological and technical complications. This randomized controlled trial involves patients aged 18 years or older receiving dental implants for missing teeth in the posterior mandible. Participants will be randomly assigned to one of two groups one receiving a 3-unit screw-retained implant bridge supported by one hexed and one non-hexed abutment, and the other receiving a similar bridge supported by two non-hexed abutments. Both groups will receive two internal connection implants placed in healed sites with a minimum healing period of three months. The surgical procedure will follow standardized protocols, differing only by the abutment connection configuration. Participants will undergo clinical and radiographic evaluations at the time of definitive loading, six months after loading, and two years after loading. Researchers will measure changes in marginal bone levels as the primary outcome, with secondary outcomes including technical and mechanical complications, biological complications, and patient satisfaction. The study includes a one-year follow-up period for assessing these outcomes.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 48

1